Stay updated on T-DXd in HER2 Expressing Tumors Clinical Trial
Sign up to get notified when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.

Latest updates to the T-DXd in HER2 Expressing Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check17 days agoChange DetectedAccess to the NCT04482309 study details now displays a 403 Forbidden page. This blocks viewing the study record on ClinicalTrials.gov in the current session.SummaryDifference0.5%

- Check24 days agoChange DetectedThe page now renders a 403 Forbidden error, replacing the study-record content with a generic error page and navigation/footer, indicating restricted access to the study record.SummaryDifference19%

- Check31 days agoChange DetectedRevision: v3.7.0 appears instead of Revision: v3.6.6, signaling a recent site update rather than a change to the study details or content.SummaryDifference0.0%

- Check45 days agoChange DetectedThis update shows the site/versioning revision to v3.6.6. It indicates a maintenance release that does not modify the study information presented on the page.SummaryDifference0.0%

- Check52 days agoChange DetectedThe study identifiers section now includes a 2023 U.S. NIH Grant/Contract entry, reflecting NIH funding attribution for this trial.SummaryDifference0.0%

Stay in the know with updates to T-DXd in HER2 Expressing Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.